ReviewKidney international reports2021
A Fresh Perspective on Monoclonal Gammopathies of Renal Significance.
Review in Kidney international reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Monoclonal and monotypic immunoglobulin-related kidney diseases in young people: literature review including evolving entities.Pediatric nephrology (Berlin, Germany) · 2026Review
- Article
- Proliferative glomerulonephritis with monoclonal immunoglobulin deposits masquerading as renal-specific thrombotic microangiopathy.BMJ case reports · 2025Article
- IgA nephropathy with monotypic IgA-κ deposits: a case report and literature review.Frontiers in medicine · 2025Article
- Rituximab Combined with Steroid and Tacrolimus Treats Proliferative Glomerulonephritis with Monoclonal IgG Deposits: A Case Report and Review of the Literature.Current medicinal chemistry · 2024Review
- IgM kappa proliferative glomerulonephritis with monoclonal immunoglobulin deposition complicated with nocardiosis dermatitis: a case report and review of literature.Frontiers in medicine · 2024Article
- Triple monoclonal protein-related kidney lesions in a patient with plasma cell dyscrasia: a case report.Frontiers in nephrology · 2024Article
- Article
- Fibrillary Glomerulonephritis and Monoclonal Gammopathy: Potential Diagnostic Challenges.Frontiers in oncology · 2022Review
- Editorial: The Role of Microorganisms in Multiple Myeloma.Frontiers in immunology · 2022Article
- Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder.Frontiers in immunology · 2022Article
- A Review on the Diagnosis and Treatment of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits.International journal of general medicine · 2022Review
- Evolution of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits Over a Decade.Indian journal of nephrologyArticle
- Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits: An Immunologic Crossroads.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal gammopathies of renal significance (MGRS) encompass a remarkable variety of kidney diseases that result from intrinsic nephrotoxic properties of certain monoclonal Igs or their subunits. Effective disease-modifying treatments rely on the targeting of a malignant B-cell clone that may be demonstrable but often is quite hypothetical. Hence, convincing arguments for the genuine monoclonal character of the causative mono-isotypic Ig tissue deposits is needed for design of appropriate treatment strategies. The purpose of this article was to critically analyze distinct situations of suspected MGRS that occur in the practice of pathologists, nephrologists, hematologists, and immunologists. A particular focus of interest is the group of conditions known as proliferative glomerulonephritis with mono-isotypic immunoglobulin deposits (PGNMIDs), which illustrates the difficulties and ambiguities surrounding a definitive assignment of MGRS status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.